UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial

Annals of oncology, 2019-04, Vol.30 (4), p.567-574

2019

Volltextzugriff (PDF)

Facial swelling and somnolence in a patient with cancer

QJM : An International Journal of Medicine, 2013-03, Vol.106 (3), p.283-284

2013

Volltextzugriff (PDF)

Clinical outcomes following Recurrence Score-based therapy in N+ ER+ breast cancer: a cohort study

Breast (Edinburgh), 2017-03, Vol.32, p.S106-S106

2017

Volltextzugriff (PDF)

1963 First prospective outcome data in 930 patients with more than 5 year median follow up in whom treatment decisions in clinical practice have been made incorporating the 21-Gene Recurrence Score

European journal of cancer (1990), 2015-09, Vol.51, p.S321-S321

2015

Volltextzugriff (PDF)

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

The New England journal of medicine, 2019-12, Vol.381 (25), p.2403-2415

2019

Volltextzugriff (PDF)

A key requirement for CD300f in innate immune responses of eosinophils in colitis

Mucosal immunology, 2017-01, Vol.10 (1), p.172-183

2017

Volltextzugriff (PDF)

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

The New England journal of medicine, 2016-12, Vol.375 (22), p.2154-2164

2016

Volltextzugriff (PDF)

Structural and functional aspects of the multiplicity of Neu differentiation factors

Molecular and Cellular Biology, 1994-03, Vol.14 (3), p.1909-1919

1994

Volltextzugriff (PDF)

Neu Differentiation Factors: A Family of Alternatively Spliced Neuronal and Mesenchymal Factors

Experimental biology and medicine (Maywood, N.J.), 1994-07, Vol.206 (3), p.221-227

1994

Volltextzugriff (PDF)

Abstract P1-07-14: Real-life analysis evaluating >1000 N0/N1mi estrogen receptor (ER)+ breast cancer patients for whom treatment decisions incorporated the 21-gene recurrence score (RS) result: Clinical outcomes with median follow up of > 9 years

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-07-14

2018

Volltextzugriff (PDF)

LBA3 - VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC)

Annals of oncology, 2019-10, Vol.30, p.v895-v896

2019

Volltextzugriff (PDF)

LBA3VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC)

Annals of oncology, 2019-10, Vol.30, p.v895-v896

2019

Volltextzugriff (PDF)

Ten-year clinical outcomes in >1000 node-negative (N0) Estrogen Receptor (ER)+ breast cancer (BC) patients (Pts) where treatment decisions incorporated the Recurrence Score Results: a registry analysis using TAILORx categorization

Breast (Edinburgh), 2019-03, Vol.44, p.S102

2019

Volltextzugriff (PDF)

P249 - Ten-year clinical outcomes in >1000 node-negative (N0) Estrogen Receptor (ER)+ breast cancer (BC) patients (Pts) where treatment decisions incorporated the Recurrence Score Results: a registry analysis using TAILORx categorization

Breast (Edinburgh), 2019-03, Vol.44, p.S102-S102

2019

Volltextzugriff (PDF)

First prospectively-designed outcome study in estrogen receptor (ER)+ breast cancer (BC) patients (pts) with N1mi or 1-3 positive nodes in whom treatment decisions in clinical practice incorporated the 21-gene recurrence score (RS) result

Annals of oncology, 2016-10, Vol.27, p.vi44-vi44

2016

Volltextzugriff (PDF)

P251 - Clinical outcomes following Recurrence Score-based therapy in N+ ER+ breast cancer: a cohort study

Breast (Edinburgh), 2017-03, Vol.32, p.S106-S106

2017

Volltextzugriff (PDF)

Abstract P5-08-02: Real-life analysis evaluating 1594 N0/Nmic breast cancer patients for whom treatment decisions incorporated the 21-gene recurrence score result: 5-year KM estimate for breast cancer specific survival with recurrence score results ≤30 is >98

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P5-P5-08-02

2016

Volltextzugriff (PDF)

Abstract P5-20-06: RAD001 (Everolimus) in combination with Letrozole in the treatment of postmenopausal women with estrogen receptor positive Metastatic Breast cancer after failure of hormonal therapy – a phase II study

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.P5-P5-20-06

2012

Volltextzugriff (PDF)

Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients

Bone marrow transplantation (Basingstoke), 2003-04, Vol.31 (8), p.655-661

2003

Volltextzugriff (PDF)

The recurrence score and chemotherapy treatment in node-positive, ER+ early-stage breast cancer patients in Israel

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.6075-6075

2010

Volltextzugriff (PDF)

Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial

Annals of oncology, 2019-04, Vol.30 (4), p.567

2019

Volltextzugriff (PDF)

A prospective study of the impact of the 21-gene recurrence score assay on treatment decisions in N-, ER+ early stage breast cancer patients

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.11008-11008

2007

Volltextzugriff (PDF)

Longitudinal analysis of trastuzumab use in metastatic breast cancer

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.11513-11513

2007

Volltextzugriff (PDF)

Abstract P4-21-17: BELIS: Safety and tolerability of at home administration of trastuzumab (Herceptin®) subcutaneous for the treatment of patients with HER2-positive early breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P4-P4-21-17

2017

Volltextzugriff (PDF)

1 – 25 von 114

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(103)
Mit Volltextzugriff
(97)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial

Facial swelling and somnolence in a patient with cancer

Clinical outcomes following Recurrence Score-based therapy in N+ ER+ breast cancer: a cohort study

1963 First prospective outcome data in 930 patients with more than 5 year median follow up in whom treatment decisions in clinical practice have been made incorporating the 21-Gene Recurrence Score

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

A key requirement for CD300f in innate immune responses of eosinophils in colitis

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

Structural and functional aspects of the multiplicity of Neu differentiation factors

Neu Differentiation Factors: A Family of Alternatively Spliced Neuronal and Mesenchymal Factors

Abstract P1-07-14: Real-life analysis evaluating >1000 N0/N1mi estrogen receptor (ER)+ breast cancer patients for whom treatment decisions incorporated the 21-gene recurrence score (RS) result: Clinical outcomes with median follow up of > 9 years

LBA3 - VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC)

LBA3VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC)

VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC)

Ten-year clinical outcomes in >1000 node-negative (N0) Estrogen Receptor (ER)+ breast cancer (BC) patients (Pts) where treatment decisions incorporated the Recurrence Score Results: a registry analysis using TAILORx categorization

P249 - Ten-year clinical outcomes in >1000 node-negative (N0) Estrogen Receptor (ER)+ breast cancer (BC) patients (Pts) where treatment decisions incorporated the Recurrence Score Results: a registry analysis using TAILORx categorization

First prospectively-designed outcome study in estrogen receptor (ER)+ breast cancer (BC) patients (pts) with N1mi or 1-3 positive nodes in whom treatment decisions in clinical practice incorporated the 21-gene recurrence score (RS) result

P251 - Clinical outcomes following Recurrence Score-based therapy in N+ ER+ breast cancer: a cohort study

Abstract P5-08-02: Real-life analysis evaluating 1594 N0/Nmic breast cancer patients for whom treatment decisions incorporated the 21-gene recurrence score result: 5-year KM estimate for breast cancer specific survival with recurrence score results ≤30 is >98

Abstract P5-20-06: RAD001 (Everolimus) in combination with Letrozole in the treatment of postmenopausal women with estrogen receptor positive Metastatic Breast cancer after failure of hormonal therapy – a phase II study

Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients

The recurrence score and chemotherapy treatment in node-positive, ER+ early-stage breast cancer patients in Israel

Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial

A prospective study of the impact of the 21-gene recurrence score assay on treatment decisions in N-, ER+ early stage breast cancer patients

Longitudinal analysis of trastuzumab use in metastatic breast cancer

Abstract P4-21-17: BELIS: Safety and tolerability of at home administration of trastuzumab (Herceptin®) subcutaneous for the treatment of patients with HER2-positive early breast cancer

Suchergebnisse filtern